BMRA
$2.08
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnosti...
Recent News
How Biomerica Deal Expands Henry Schein’s (HSIC) Diagnostic Ambitions and Alters Its Investment Narrative
In October 2025, Biomerica announced a marketing services arrangement with Henry Schein to promote its inFoods IBS test throughout the United States, excluding New York State, utilizing Henry Schein's network of more than 400 sales representatives targeting primary care and gastroenterology practices. This collaboration highlights Henry Schein's evolving presence in precision diagnostics, following clinical evidence for the inFoods test published in a leading gastrointestinal journal showing...
Biomerica receives approval in UAE for at-home ulcer test
The company is collaborating with local companies and healthcare providers to distribute the ulcer test.
Biomerica’s kidney disease test gains approval for sale in UAE
The diagnostic tool delivers outcomes within ten minutes from a urine sample.
Biomerica Third Quarter 2025 Earnings: US$0.061 loss per share (vs US$0.11 loss in 3Q 2024)
Biomerica ( NASDAQ:BMRA ) Third Quarter 2025 Results Key Financial Results Revenue: US$1.12m (up 10.0% from 3Q 2024...